by clicking the arrows at the side of the page, or by using the toolbar.
by clicking anywhere on the page.
by dragging the page around when zoomed in.
by clicking anywhere on the page when zoomed in.
web sites or send emails by clicking on hyperlinks.
Email this page to a friend
Search this issue
Index - jump to page or section
Archive - view past issues
Australian Journal of Pharmacy : October 2005
products ethical products different strengths—10mg, 20mg, 40mg and 80mg. Every pack has a CMI for the patient and a dose reminder sticker which, when stuck in a prominent place, will help to remind patients to take their daily dose. Business Builder Members dealing directly with Douglas will receive additional rewards on top of the competitive discounts. The introduction of the Simvastatin-DP range follows the company’s recent launch of branded products such as Klorane Dry Shampoo, Uriclense, Curosurf, and Micellaire. ¦ Scientific Working Group on Influenza (ESWI) congress in Malta showed that the oral influenza treatment Tamiflu (oseltamivir), significantly decreases the risk of death and influenza-related complications such as pneumonia. The study results support existing clinical trial evidence where Tamiflu has demonstrated a 67 per cent reduction in secondary complications, by providing a ‘real-setting’ view of the benefits of Tamiflu use in everyday clinical practice. The first study, using data from a large Flu treatment reduces death risk R ESULTS from two studies presented recently at the European Douglas enters simvastatin market D OUGLAS Pharmaceuticals has launched its range of Simvastatin-DP, presented as blister packs in four a significantly reduced risk of pneumonia, death and possibly heart attacks, compared to untreated patients. The second study, using data from the US health insurer, investigated the incidence of pneumonia, heart attacks and death during the month following influenza diagnosis in patients who either received no medication or who were prescribed Tamiflu. Tamiflu treatment was associated with Toronto Invasive Bacterial Disease Network, found that Tamiflu treatment in hospitalised influenza patients was associated with a significant clinical benefit and a reduced risk of death in patients treated within three days of symptom onset. The rescheduling of Tamiflu (oseltamivir) is back on the agenda with regulatory authorities set to consider moving it from prescription-only (S4) to pharmacist-only (S3). The National Drugs and Poisons Scheduling Committee deferred its decision to reschedule the antiviral therapy last year in order to seek further advice. The committee will reconsider the issue at its October meeting. ¦ New PBS listing for colon cancer drug T HE Commonwealth Government has added Eloxatin, an injectable cancer chemotherapy drug, onto the PBS from 1 October. Eloxatin has been available on the PBS for some time for the treatment of metastatic (disseminated) colorectal cancer. The extension of this listing will make it available on a subsidised basis for those with Stage III (Dukes C) colon cancer who have undergone surgery for removal of the primary tumour. ¦ THE AUSTRALIAN JOURNAL OF PHARMACY VOL 86 OCTOBER 2005 ? 809